FOXO4 10MG

FOXO4-DRI functions as a competitive peptide antagonist that disrupts the critical survival interaction between FOXO4 and p53 in senescent cells, triggering a process called Targeted Apoptosis of Senescent Cells (TASC).[1]

Primary Target & Binding Characteristics

Property	Detail	Evidence
Primary Target	FOXO4-p53 protein-protein interaction interface	Baar et al. (2017)[1]
Specific Binding Site on p53	Transactivation Domain 2 (TAD2) of p53	Bourgeois et al. (2025) NMR structure[2]
Binding Dynamics	Both FOXO4-DRI and p53 TAD2 are intrinsically disordered; fold synergistically upon binding to form a transiently folded complex	Bourgeois et al. (2025)[2]
Affinity Modulation	Phosphorylation of p53 at Ser46 and Thr55 significantly enhances FOXO4-DRI binding affinity	Bourgeois et al. (2025)[2]
HIV-TAT Contribution	Cationic HIV-TAT residues contribute additional contacts with p53 TAD2, stabilizing the interaction	Bourgeois et al. (2025)[2]
Cell Penetration	Intracellular uptake within 2–4 hours; detectable for ≥72 hours	Baar et al. (2017)[1]

The Senescence Lock (Pre-Treatment State)

In senescent cells, FOXO4 is upregulated and physically interacts with p53 within the nucleus, specifically localizing to PML bodies (Promyelocytic Leukemia bodies) and DNA-SCARS (DNA Segments with Chromatin Alterations Reinforcing Senescence). This binding sequesters p53 in the nucleus, preventing it from initiating pro-apoptotic functions — effectively keeping the senescent cell in a suspended "zombie" state.[1][3]

Downstream Signaling Cascade (TASC Pathway)

Step	Event	Molecular Detail
1. Competitive Inhibition	FOXO4-DRI competes with endogenous FOXO4 for p53 binding	Binds p53 TAD2 with high affinity, displacing endogenous FOXO4[1][2]
2. Nuclear Exclusion	Liberated p53 is excluded from the nucleus	p53 released from PML bodies / DNA-SCARS[1]
3. Mitochondrial Translocation	Active, mono-ubiquitinated p53 translocates to mitochondria	Transcription-independent apoptosis pathway[1]
4. BAX/BAK Activation	p53 interacts with BAX and BAK (pro-apoptotic Bcl-2 family members)	Mitochondrial outer membrane permeabilization (MOMP)[1][5]
5. Cytochrome C Release	BAX/BAK pores release Cytochrome C into the cytosol	Initiates the intrinsic apoptosis cascade[1]
6. Caspase Activation	Cytochrome C triggers cleavage of Caspase-3 and Caspase-7	Terminal effector caspases execute apoptosis[1][5]
7. Selective Senolysis	Senescent cell undergoes intrinsic apoptosis and is eliminated	Non-senescent cells unaffected (low FOXO4, no dependency on FOXO4-p53 axis)[1]

Cellular & Tissue-Level Effects

Effect	Detail	Evidence
Senolysis	Selective elimination of senescent fibroblasts (IMR90), chondrocytes, and Leydig cells; 11.73-fold selectivity over non-senescent cells	Baar et al. (2017); Huang et al. (2021)[1][6]
SASP Suppression	Downregulation of IL-6, IL-1β, TNF-α, TGF-β, and other pro-inflammatory cytokines	Zhang et al. (2020); Hu et al. (2026)[4][5]
Marker Modulation	Decreased p16 and p21 expression; increased Ki-67 (proliferation marker) and Lamin B1 (nuclear envelope marker)	Hu et al. (2026)[5]
Renal Restoration	Normalized plasma urea and creatinine; reduced tubular senescence markers	Baar et al. (2017)[1]
Testosterone Restoration	Selective apoptosis of senescent Leydig cells; improved testicular microenvironment; restored testosterone secretion	Zhang et al. (2020)[4]
Vascular Health	Reduced aortic wall thickness, reduced ROS levels, improved endothelial-dependent vasodilation, reduced Pulse Wave Velocity	Hu et al. (2026)[5]

Selectivity vs. Related Compounds

Comparison	FOXO4-DRI	Comparator
vs. ABT-737 / Navitoclax (BCL-2 inhibitors)	No thrombocytopenia; targets p53/FOXO4 axis specifically	Causes low platelet counts by affecting non-senescent cells[1]
vs. Dasatinib + Quercetin	Peptide-based; single-target mechanism (FOXO4-p53); DRI stability	Small molecule combination; multi-target kinase inhibition
vs. CL04183 (4th-generation)	Original compound; shorter half-life; narrower therapeutic window at high doses	Enhanced binding affinity; improved liver enzyme stability; broader therapeutic window[2]
vs. Endogenous FOXO4	Antagonist: competes for p53 to trigger apoptosis; protease-resistant DRI form	Agonist of senescence maintenance: sequesters p53 to keep senescent cells alive[1]

FOXO Family Specificity: The peptide design focused on a region of FOXO4 that differs from FOXO1 and FOXO3 to minimize cross-reactivity with these essential transcription factors. Cross-species conservation of the binding domain allows direct translational studies between mice and humans.[1]

FOXO4-DRI is utilized in preclinical research to study the effects of clearing senescent cells (senolysis) across 9+ research domains:

1. General Aging & Frailty — FOXO4-DRI restores tissue homeostasis in naturally aged mice (104–130 weeks). Benefits include improved fur density, increased physical activity (running wheel activity), improved responsiveness, and reduced p16-driven bioluminescence (senescence burden). Treatment of Xpd^TTD/TTD fast-aging mice yielded fur insulation restoration (approaching wildtype levels) and increased running from 1.37 km/day to near-wildtype levels.[1]
2. Chemotherapy-Induced Toxicity — In Doxorubicin-treated C57BL/6J mice, FOXO4-DRI (5 mg/kg i.v., 3 doses) neutralized chemotherapy-induced liver toxicity (normalized plasma AST), prevented body weight loss, and reduced IL-6 and FOXO4 foci in liver tissue.[1]
3. Renal Function Decline — In both fast-aging and naturally aged mice, FOXO4-DRI normalizes plasma urea and creatinine levels, restoring kidney filtering capacity and reducing tubular senescence markers. Significant reductions observed 30 days after 3 i.p. injections.[1]
4. Male Hypogonadism / Testosterone Deficiency — In aged male mice (20–24 months), FOXO4-DRI selectively induces apoptosis in senescent Leydig cells, reducing SASP factors (IL-1β, IL-6, TGF-β), improving the testicular microenvironment, and significantly restoring serum testosterone levels (p<0.05).[4]
5. Cardiovascular Aging & Endothelial Dysfunction — FOXO4-DRI reduces reactive oxygen species (ROS) in the aorta, suppresses vascular aging markers (p16, p21), thins the aortic wall, lowers Pulse Wave Velocity (improved elasticity), and improves endothelial-dependent vasodilation in both naturally aged and D-galactose progeroid mice.[5]
6. Pulmonary Fibrosis — FOXO4-DRI ameliorates bleomycin-induced pulmonary fibrosis by targeting senescent myofibroblasts, downregulating extracellular matrix receptor interaction pathways, attenuating collagen deposition, and increasing Type 2 alveolar epithelial cells (AEC2).[8][9]
7. Osteoarthritis & Cartilage Regeneration — In expanded human chondrocytes, FOXO4-DRI (25 µM, 5 days) selectively removed >50% of senescent cells (PDL9), reduced SA-β-gal to <5%, and decreased expression of SASP factors (IL-6, IL-8) in engineered cartilage tissue.[6]
8. Cancer & Metastasis — FOXO4-DRI is being explored against therapy-resistant and metastatic cancers (triple-negative breast cancer, metastatic colon cancer) by targeting "scarred" cancer cells that share features with senescent cells, and for radiosensitizing non-small cell lung cancer.[10][11]
9. Liver Fibrosis — FOXO4-DRI and optimized variants (CL04183) counter the CD44-high dedifferentiation state in hepatocytes driven by senescence, restoring liver function markers in fibrosis models.[10]